Appeals court sides with AstraZeneca, BMS, McKesson in saxagliptin heart failure case
A Sixth Circuit appeals court this week upheld a decision in favor of AstraZeneca, Bristol Myers Squibb and McKesson in a case alleging that diabetes products containing saxagliptin can cause heart failure.
Saxagliptin is the key ingredient in the discontinued type 2 diabetes treatments Onglyza and Kombiglyze. It’s a dipeptidyl peptidase-4 (DPP-4) inhibitor, designed to help lower blood sugar along with diet and exercise. But in 2016, an FDA safety review found that saxagliptin and another DPP-4 inhibitor called alogliptin may increase patients’ risk of heart failure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
